Hepatology — L6: Vascular & Immune Hepatic Diseases

📚 Lecture Overview

This lecture covers vascular and immune-mediated hepatic diseases, focusing specifically on Budd-Chiari syndrome, acute portal vein thrombosis, and autoimmune hepatitis. Understanding these conditions is critical for diagnosing acute liver presentations, managing thrombotic and inflammatory complications, and preventing irreversible liver failure.

🎯 Key Concepts & Definitions

Budd-Chiari Syndrome (BCS): The obstruction of hepatic venous outflow located anywhere from the small hepatic venules up to the entrance of the inferior vena cava (IVC) into the right atrium.
Acute Portal Vein Thrombosis (PVT): The recent formation of a thrombus within the main portal vein and/or its right or left branches, potentially extending into mesenteric or splenic veins.
Autoimmune Hepatitis (AIH): A non-resolving chronic liver disease primarily affecting women, characterized by hypergammaglobulinaemia, circulating autoantibodies, interface hepatitis, and a favorable response to immunosuppression.
Interface Hepatitis: A morphological feature seen on liver histology in AIH, characterized by an inflammatory infiltrate spilling into the hepatic parenchyma.
Transjugular Intrahepatic Portosystemic Shunt (TIPS): A procedure that connects a branch of the portal vein to a hepatic vein using a PTFE stent to transform the portal system into an outflow tract.

📖 Main Content

Vascular Hepatic Diseases: Etiology

Thrombotic risk factors for hepatic vascular diseases include:
- Inherited thrombophilia: Protein C deficiency, protein S deficiency, antithrombin deficiency
- Acquired factors: Myeloproliferative neoplasms, paroxysmal nocturnal hemoglobinuria
- Hormonal factors: Oral contraceptives, pregnancy

Budd-Chiari Syndrome (BCS)

Clinical Presentation: Highly heterogeneous, ranging from asymptomatic (due to large collaterals) to fulminant hepatic failure. Common symptoms include ascites, hepatomegaly, abdominal pain, esophageal varices, and gastrointestinal bleeding.
Diagnosis:
Doppler ultrasound is the first-line investigation (sensitivity > 75%).
MR imaging and CT evaluation provide diagnostic confirmation.
Venography is reserved for uncertain cases.
Treatment Algorithm:
Anticoagulation therapy with low molecular weight heparin (LMWH) for 5-7 days, transitioned to oral vitamin K antagonists (VKA) aiming for an INR between 2 and 3 for an indefinite period.
Angioplasty or stenting for partial or segmental obstructions.
TIPS to decompress the portal system.
Liver Transplantation (LT) for patients failing less invasive approaches or presenting with severe acute hepatic failure.

Acute Portal Vein Thrombosis (PVT)

Clinical Presentation: Acute abdominal pain occurs in 90% of patients. Ascites is present in 50%. Liver tests often show normal or only mildly/transiently abnormal results.
Complications: Intestinal infarction is the most concerning immediate complication with a mortality rate of up to 60%. Warning signs include persisting severe abdominal pain despite anticoagulation, organ failure, massive ascites, and rectal bleeding.
Diagnosis & Treatment:
Confirmed via contrast-enhanced CT and/or MR imaging (Doppler ultrasound is first-line).
Treatment targets preventing mesenteric infarction and achieving portal vein recanalisation.
Initiate LMWH immediately, followed by VKA (INR 2-3) for at least 6 months.
Follow-up CT scan at 6-12 months to assess recanalization.

Autoimmune Hepatitis (AIH)

Demographics: Bimodal age distribution (puberty and 4th-6th decades); affects females more than males (3:1 ratio).
Types of AIH:
AIH-1: Accounts for 90% of cases. Onset at any age. Positive for ANA, SMA, or anti-SLA/LP. Associated with HLA DR3, DR4, and DR13.
AIH-2: Accounts for 10% of cases. Usually starts in childhood/young adulthood with acute/advanced severity. Positive for anti-LKM1, anti-LC1, and anti-LKM3. Associated with HLA DR3 and DR7. Frequent treatment failure and relapses.
Diagnosis:
Predominantly hepatitic pattern with elevated aminotransferases and normal/moderately elevated cholestatic enzymes.
Elevated serum IgG or gamma-globulins in ~85% of patients.
Liver biopsy is a prerequisite, demonstrating interface hepatitis, periportal necrosis, and hepatocyte rosetting.
Treatment:
Predniso(lo)ne (0.5–1 mg/kg/day) as initial therapy.
Azathioprine (50 mg/day initially, up to 1-2 mg/kg maintenance) is added after two weeks (when bilirubin is < 6 mg/dl).
Treatment must continue for at least 3 years and at least 2 years following complete biochemical remission (normalization of IgG and transaminases).

📊 Visual Learning

flowchart TD A[Vascular Symptoms] --> B{First Line Scan} B -->|Doppler US| C[Confirm Obstruction] C --> D[Start LMWH] D --> E[Transition to VKA] E --> F[Target INR 2 to 3]

mindmap root("Autoimmune Hepatitis") "AIH Type 1" "90 percent of cases" "ANA and SMA positive" "HLA DR3 DR4 DR13" "AIH Type 2" "Childhood onset" "Anti-LKM1 positive" "Frequent relapses" "Diagnosis and Treatment" "Liver biopsy required" "Prednisone and Azathioprine" "Remission normalization"

sequenceDiagram participant P as Patient participant D as Doctor participant L as Lab/Imaging P ->> D: Presents with Abdominal Pain D ->> L: Order Doppler Ultrasound and CT L ->> D: Confirm Portal Vein Thrombosis D ->> P: Prescribe LMWH and VKA Therapy

💡 Important Points to Remember

Budd-Chiari definition: Obstruction of hepatic venous outflow from small venules to the IVC.
Budd-Chiari first-line test: Doppler ultrasound.
Anticoagulation target: Target INR between 2 and 3 for both Budd-Chiari and acute PVT.
Acute PVT danger: Intestinal infarction is the most feared complication, carrying up to a 60% mortality rate.
AIH Gender ratio: Female to male ratio is 3:1.
AIH Hallmark lab finding: Elevated IgG / gamma-globulins and positive autoantibodies.
AIH Diagnostic requirement: Liver biopsy showing interface hepatitis is a mandatory prerequisite.
AIH First-line drugs: Prednisone combined with Azathioprine (added after two weeks).
Treatment duration for AIH: Continue for at least 3 years and 2 years past biochemical remission.
Common Trap: Confusing AIH-1 (common, adult/any age, ANA/SMA positive) with AIH-2 (childhood onset, anti-LKM1 positive, frequent treatment failure).

⚠️ Common Exam Questions

Examiners frequently test students by presenting clinical scenarios where complications like intestinal infarction in acute PVT are disguised as simple post-procedural pain.
- MCQ Trick: Examiners will state that liver biopsy is optional in AIH or can be replaced entirely by autoantibody testing. Correction: Liver biopsy is always a prerequisite for definitive AIH diagnosis.
- Short-Answer Trap: Asking for the exact target INR in thrombotic liver diseases. Students often forget the therapeutic range is 2 to 3.
- Differentiation Trap: Conflating the treatment duration of AIH (minimum 3 years, and 2 years post-remission) with acute PVT anticoagulation duration (at least 6 months).

📝 Quick Review Checklist

I can define Budd-Chiari syndrome and its clinical picture
I understand the management of Budd-Chiari Syndrome
I can define acute portal vein thrombosis and recognize its complications
I can define Autoimmune hepatitis (AIH) and its types
I recognize the management plan of AIH regarding diagnosis and treatment

📚 Hepatology — L6: Vascular & Immune Hepatic Diseases